First, clonal architecture of the cancer samples could not be fully assessed with the available single-time point genomic data; in theory, the coexisting alterations could be present in different tumor subclones, though a previous study showed that concomitant BRAF and RAS alterations were mostly present in the same tumor cell populations.16 Second, some rare non-V600 BRAF alterations are underrepresented in the genomic databases; thus their RAS dependency cannot be reliably assessed with the approach in the study. The gene discussed is BRAF; the disease is neoplasm.